North East and North Cumbria
ICS Formulary
 
back
3 Respiratory system

*Important*

The NENC ICB Respiratory Network recommends that all inhalers should be prescribed by brand for patient safety, to ensure that the correct device is dispensed to support correct technique and avoid patient confusion and medication errors.

Choice of inhaler device should be based on patient ability to use. Devices should be chosen based on availability for the type of drug to be prescribed and the patient’s ability to use it.

Refer to local guidelines for information on preferred options.

Note: All new patients should be started on the updated formulary choices as per local/national guidelines.

When inhalers are removed from the formulary, existing, stable, patients should continue to receive the non-formulary device. Treatment should not be changed unless a full face to face review has been conducted.

03-04-02 Monoclonal antibodies

Benralizumab Fasenra®
Formulary
  • 30mg/1ml solution for injection (pre-filled devices)
  • Approved for treating severe eosinophilic asthma in adults in line with NICE and NHS England Commissioning Policy.

 

Link  NICE TA565: Benralizumab for treating severe eosinophilic asthma

Red View adult BNF  View SPC online  View childrens BNF  HCD
Dupilumab Dupixent®
Formulary
  • 200mg/1.14ml & 300mg/2ml solution for injection
  • Approved for or treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over in line with NICE
Link  MHRA Drug Safety Update Nov 2022: Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management
Link  NICE TA751: Dupilumab for treating severe asthma with type 2 inflammation

Red View adult BNF  View SPC online  View childrens BNF  HCD
Mepolizumab Nucala®
Formulary
  • 100mg/1ml solution for injection (pre-filled devices)
  • Approved for the treatment of severe refractory eosinophilic asthma in line with NICE and NHS England Commissioning Policy.
Link  NICE TA671: Mepolizumab for treating severe eosinophilic asthma

Red View adult BNF  View SPC online  View childrens BNF  HCD
Omalizumab Xolair®
Formulary
  • 75mg/0.5ml & 150mg/1ml solution for injection (pre-filled devices)
  • Only approved for use in accordance with NICE guidance. 
Link  NICE TA278: Omalizumab for treating allergic asthma
Link  NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Link  NICE TA678: Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)

Red View adult BNF  View SPC online  View childrens BNF  HCD
Reslizumab Cinquil®
Formulary
  • 10 mg/mL concentrate for solution for infusion
  • Approved for the treatment of severe eosinophilic asthma in line with NICE and NHS England Commissioning Policy
Link  NICE TA479 Reslizumab for treating severe eosinophilic asthma

Red View adult BNF  View SPC online  View childrens BNF  HCD
Tezepelumab Tezspire®
Formulary
  • 210mg/1.91ml solution for injection (pre-filled devices)
  • Approved for treating severe asthma in paeople 12 years and over in line with NICE and NHS England Specialised Commissioning Policy (SSC2536)
  • Only available from:
    • The Newcastle upon Tyne Hospitals NHS Foundation Trust
    • South Tyneside and Sunderland NHS Foundation Trust
    • South Tees Hopsitals NHS Foundation Trust
Link  NICE TA880: Tezepelumab for treating severe asthma

Red View adult BNF  View SPC online  View childrens BNF  HCD